SHANGHAI/SUZHOU, China ¨C China¡¯s vaccine developers stuck with unused mRNA COVID-19 shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue.
Three Chinese companies ¡ª Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics ¡ª came up with mRNA vaccines that won limited emergency approvals in Asia.
However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official said.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.